Clinical efficacy and safety of daratumumab-carfilzomib based therapy in newly diagnosed multiple myeloma: A retrospective cohort analysis
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7579
Abstract: Introduction: Carfilzomib (K) and daratumumab (D) combination has earning FDA approval for relapsed/refractory multiple myeloma. The MASTER trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) therapy show significant clinical efficacy and favorable safety profile in… read more here.
Keywords: multiple myeloma; treatment; daratumumab carfilzomib; therapy ... See more keywords
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood Advances"
DOI: 10.1182/bloodadvances.2024014417
Abstract: Key Points • Dara-KRd–based, MRD-adapted treatment yielded high stringent CR rates and MRD negativity that improved over time.• Results support randomized studies of therapy de-escalation for patients who are MRD(-) and escalation for MRD(+) after… read more here.
Keywords: driven phase; daratumumab carfilzomib; phase study; carfilzomib lenalidomide ... See more keywords